Aptevo to present multispecific CD40 platform data at SITC 2026

Aptevo Therapeutics Inc. (Nasdaq: APVO) said on October 14, 2026 that it will present its multispecific immunotherapy platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, scheduled for November 4 to 8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.¹

The presentation will cover Aptevo's CD40-directed multispecific portfolio and the company's approach to combining innate and adaptive immune activity within the tumor microenvironment.¹ According to the company, solid tumors can suppress or disrupt anti-tumor immune responses, which limits the immune system's ability to recognize and attack cancer cells.¹ Aptevo said its tumor-targeted CD40-activating molecules are built to also engage the cells responsible for killing tumor cells, an approach the company described as a way to concentrate immune activation at the tumor site and drive a stronger overall anti-tumor response, as stated in the release "designed to help overcome that challenge by localizing immune activation to the tumor and promoting a more complete anti-tumor response."¹

The specific talk is titled "Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity," abstract number 1060, with Michelle Nelson, PhD, listed as presenter among others.¹ Aptevo said a copy of the presentation will be posted to the Publications page of its website after the meeting.¹

Aptevo describes itself as a clinical-stage biotechnology company developing novel multispecific immunotherapies for cancer, with pipeline candidates built on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies designed to engage the immune system through differentiated mechanisms of action.¹ The filing was signed by Daphne Taylor, Senior Vice President and Chief Financial Officer, dated October 14, 2026.